GC Biopharma (006280.KS) Earnings Analysis

GC Biopharma (006280.KS) has no confirmed upcoming earnings date. Last quarter (2026-05-08) it beat with EPS 1,751.52 KRW vs -126.2 KRW est (+1487.9%). It has beaten estimates in 4/7 recent quarters (57%). Trailing P/E -101.12.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 006280.KS next report earnings?

No confirmed upcoming earnings date is currently scheduled for 006280.KS. This page updates as the calendar is published.

006280.KS earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-081,751.52 KRW-126.2 KRW+1487.9%Beat
2026-01-26-7,555.4 KRW-3,201.46 KRW-136%Miss
2025-08-013,328.58 KRW1,312.9 KRW+153.5%Beat
2025-04-302,602 KRW-1,049.15 KRW+348%Beat
2025-01-24-2,391.48047 KRW759 KRW-415.1%Miss
2024-11-012,915 KRW1,005 KRW+190%Beat
2024-08-05-608 KRW758.94 KRW-180.1%Miss

Beat rate: 4/7 (57%) over reported quarters with consensus data.

006280.KS valuation and analyst view

Trailing P/E-101.12
Trailing EPS-1,212.63583 KRW
Price / book1.15
Dividend yield1.22%
Market cap1354.74B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is GC Biopharma (006280.KS)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for 006280.KS. This page updates as the calendar is published.

Did 006280.KS beat earnings last quarter?

In its 2026-05-08 report, 006280.KS posted EPS of 1751.52 KRW versus a -126.2 KRW estimate — a beat of 1487.9%.

What is 006280.KS's earnings track record?

Over the last 7 reported quarters with consensus data, 006280.KS beat estimates 4 times (57%).

What is 006280.KS's current P/E ratio and EPS?

006280.KS trades at a trailing P/E of -101.12 on trailing EPS of -1212.6358320970417 KRW.

What do analysts rate 006280.KS?

006280.KS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.